

VERSION WITH MARKINGS TO SHOW CHANGES MADE**In the Claims:****Claims 3 – 6, 10, 13 had been amended as follows:**

3. A composition ~~as claimed in~~ according to claim 1 or claim 2 wherein the hydrophilic component comprises ethanol, 1,2-propylene glycol or a polyethylene glycol.
4. A composition ~~as claimed in any preceding~~ according to claim 1 wherein the surfactant is selected from the group consisting of polyoxyethylenes, polyglycerols and related polyols, and polyalkylene oxide copolymers.
5. A composition ~~as claimed in any preceding~~ according to claim 1 wherein the surfactant is selected from the group consisting of a polyoxyethylene castor oil, a polyoxyethylene alkyl ether, and a polysorbate.
6. A composition ~~as claimed in any preceding~~ according to claim 1 wherein the surfactant has an HLB value of greater than 10 and the composition further comprises a co-surfactant having an HLB value of less than 10.
10. A method of treatment for treating subjects in need of N-benzoyl-staurosporine therapy comprising administering a dispersible pharmaceutical composition according to ~~any preceding~~ claim 1 to a subject in need of such treatment.
13. A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine, said method comprising orally administering a composition according to ~~any preceding~~ claim 1 to fasted beagle dogs.